Biogen Idec, Cell Therapeutics deal

Cell Therapeutics completed its previously announced acquisition of U.S. rights to Zevalin ibritumomab tiuxetan from Biogen Idec (see BioCentury, Aug. 20, 2007). Biogen Idec received $10 million up f...